UNITED STATES
SECURITIES
AND EXCHANGE
COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of April 2016
001-36203
(Commission
File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover
Form
20-F
or Form
40-F.
Form
20-F
☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____
This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795 and 333-209037), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On April 1, 2016, Can-Fite BioPharma Ltd. issued a press release announcing that it has filed its 2015 Annual Report on 20-F with the SEC and providing a clinical pipeline update. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
2
Exhibit Index
Exhibit No | Description | |
99.1 | Press Release, dated April 1, 2016 |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Can-Fite BioPharma Ltd. | ||
Date April 1, 2016 | By: | /s/ Pnina Fishman |
Pnina Fishman | ||
Chief Executive Officer |
4